{"id":"placebo-lanreotide","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Abdominal pain"},{"rate":"5-10%","effect":"Injection site reaction"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by binding to somatostatin receptors on the surface of pituitary cells, which reduces the secretion of growth hormone and other hormones. This can help to reduce symptoms associated with acromegaly and other conditions.","oneSentence":"Lanreotide is a somatostatin analogue that inhibits the release of growth hormone and other hormones.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:51:31.009Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acromegaly"},{"name":"Gastrointestinal neuroendocrine tumors"}]},"trialDetails":[{"nctId":"NCT07087054","phase":"PHASE3","title":"Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen","status":"RECRUITING","sponsor":"Crinetics Pharmaceuticals Inc.","startDate":"2025-11-19","conditions":"Carcinoid Syndrome, Carcinoid, Carcinoid Tumor","enrollment":141},{"nctId":"NCT06807437","phase":"PHASE3","title":"Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2025-05-09","conditions":"Pancreatic Carcinoma, Pancreatic Neoplasm","enrollment":274},{"nctId":"NCT03792555","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Evolve)","status":"COMPLETED","sponsor":"Crinetics Pharmaceuticals Inc.","startDate":"2019-03-11","conditions":"Acromegaly","enrollment":13},{"nctId":"NCT00353496","phase":"PHASE3","title":"Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours","status":"COMPLETED","sponsor":"Ipsen","startDate":"2006-06","conditions":"Endocrine Tumors","enrollment":264},{"nctId":"NCT01923649","phase":"PHASE2","title":"SOMATULINE Autogel 90 mg IN DUMPING SYNDROME","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2008-04","conditions":"Dumping Syndrome","enrollment":24},{"nctId":"NCT02288377","phase":"PHASE2, PHASE3","title":"A Study Evaluating Lanreotide as Maintenance Therapy in Patients With Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors (REMINET)","status":"TERMINATED","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2015-01","conditions":"Metastatic/Locally Advanced, Non-resectable, Duodeno-pancreatic Neuroendocrine Tumours","enrollment":53},{"nctId":"NCT00774930","phase":"PHASE3","title":"An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome","status":"COMPLETED","sponsor":"Ipsen","startDate":"2009-05","conditions":"Carcinoid Syndrome","enrollment":115},{"nctId":"NCT00842348","phase":"PHASE3","title":"Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero- Pancreatic Endocrine Tumour","status":"COMPLETED","sponsor":"Ipsen","startDate":"2009-02","conditions":"Non Functioning Entero-pancreatic Endocrine Tumour","enrollment":89},{"nctId":"NCT02683941","phase":"PHASE3","title":"Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumours","status":"TERMINATED","sponsor":"Ipsen","startDate":"2017-03-06","conditions":"Neuroendocrine Tumors in Lung","enrollment":77},{"nctId":"NCT00216372","phase":"PHASE3","title":"Efficacy and Safety of Lanreotide Microparticles as Palliative Treatment in Peritoneal Carcinomatosis","status":"COMPLETED","sponsor":"Ipsen","startDate":"2003-09","conditions":"Intestinal Obstruction, Carcinoma, Peritoneal Neoplasms","enrollment":80},{"nctId":"NCT00288522","phase":"PHASE2","title":"Lanreotide (Somatuline Autogel) in Thyroid-associated Ophthalmopathy Treatment","status":"TERMINATED","sponsor":"Ipsen","startDate":"2006-01","conditions":"Thyroid-Associated Ophthalmopathy","enrollment":5},{"nctId":"NCT04065165","phase":"PHASE3","title":"Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid Syndrome","status":"WITHDRAWN","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2020-04","conditions":"Small Intestinal NET, Carcinoid Heart Disease","enrollment":""},{"nctId":"NCT00234572","phase":"PHASE2, PHASE3","title":"Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With Acromegaly","status":"COMPLETED","sponsor":"Ipsen","startDate":"2000-05","conditions":"Acromegaly","enrollment":108},{"nctId":"NCT00729313","phase":"PHASE3","title":"Efficacy and Safety of Lanreotide Versus Placebo for Treatment of Patients With Digestive Fistulae","status":"COMPLETED","sponsor":"Ipsen","startDate":"2000-04","conditions":"Digestive Fistulae","enrollment":111},{"nctId":"NCT01677910","phase":"PHASE3","title":"TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)","status":"COMPLETED","sponsor":"Lexicon Pharmaceuticals","startDate":"2013-01-08","conditions":"Carcinoid Syndrome","enrollment":135},{"nctId":"NCT01731925","phase":"PHASE2","title":"A Study of Sunitinib Versus Placebo in Combination With Lanreotide in Patients With Progressive Advanced/Metastatic Midgut Carcinoid Tumors","status":"UNKNOWN","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2013-01-07","conditions":"Carcinoid Tumors","enrollment":44},{"nctId":"NCT01372007","phase":"PHASE3","title":"Influence of Somatuline Autogel 120mg on Post-operative Drainage After Total Mesorectum Excision for Rectumcarcinoma","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2011-07","conditions":"Rectal Carcinoma","enrollment":24},{"nctId":"NCT00630695","phase":"PHASE3","title":"Prevention of Lymphorrhea by Lanreotide in Axillary Dissection for Breast Cancer","status":"COMPLETED","sponsor":"University Hospital, Limoges","startDate":"2008-03","conditions":"Lymphocele","enrollment":148},{"nctId":"NCT00565097","phase":"PHASE2, PHASE3","title":"Lanreotide as Treatment of Polycystic Livers","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2007-10","conditions":"Polycystic Liver Disease, Hepatomegaly, Liver Diseases","enrollment":38}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"BILE DUCT STENOSIS"},{"count":1,"reaction":"HEPATIC FAILURE"},{"count":1,"reaction":"SEPSIS"}],"_approvalHistory":[],"publicationCount":69,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo lanreotide","genericName":"Placebo lanreotide","companyName":"University Hospital, Limoges","companyId":"university-hospital-limoges","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lanreotide is a somatostatin analogue that inhibits the release of growth hormone and other hormones. Used for Acromegaly, Gastrointestinal neuroendocrine tumors.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}